Basch Ethan, Deal Allison M, Kris Mark G, Scher Howard I, Hudis Clifford A, Sabbatini Paul, Rogak Lauren, Bennett Antonia V, Dueck Amylou C, Atkinson Thomas M, Chou Joanne F, Dulko Dorothy, Sit Laura, Barz Allison, Novotny Paul, Fruscione Michael, Sloan Jeff A, Schrag Deborah
Ethan Basch, Mark G. Kris, Howard I. Scher, Clifford A. Hudis, Paul Sabbatini, Lauren Rogak, Thomas M. Atkinson, Joanne F. Chou, Dorothy Dulko, Laura Sit, Michael Fruscione, and Deborah Schrag, Memorial Sloan Kettering Cancer Center, New York, NY; Ethan Basch, Allison M. Deal, and Antonia V. Bennett, University of North Carolina, Chapel Hill, NC; Amylou C. Dueck, Mayo Clinic, Scottsdale, AZ; Allison Barz, Children's Hospital of Philadelphia, Philadelphia, PA; Paul Novotny and Jeff A. Sloan, Mayo Clinic, Rochester, MN; and Deborah Schrag, Dana-Farber/Harvard Cancer Center, Boston, MA.
J Clin Oncol. 2016 Feb 20;34(6):557-65. doi: 10.1200/JCO.2015.63.0830. Epub 2015 Dec 7.
There is growing interest to enhance symptom monitoring during routine cancer care using patient-reported outcomes, but evidence of impact on clinical outcomes is limited.
We randomly assigned patients receiving routine outpatient chemotherapy for advanced solid tumors at Memorial Sloan Kettering Cancer Center to report 12 common symptoms via tablet computers or to receive usual care consisting of symptom monitoring at the discretion of clinicians. Those with home computers received weekly e-mail prompts to report between visits. Treating physicians received symptom printouts at visits, and nurses received e-mail alerts when participants reported severe or worsening symptoms. The primary outcome was change in health-related quality of life (HRQL) at 6 months compared with baseline, measured by the EuroQol EQ-5D Index. Secondary endpoints included emergency room (ER) visits, hospitalizations, and survival.
Among 766 patients allocated, HRQL improved among more participants in the intervention group than usual care (34% v 18%) and worsened among fewer (38% v 53%; P < .001). Overall, mean HRQL declined by less in the intervention group than usual care (1.4- v 7.1-point drop; P < .001). Patients receiving intervention were less frequently admitted to the ER (34% v 41%; P = .02) or hospitalized (45% v 49%; P = .08) and remained on chemotherapy longer (mean, 8.2 v 6.3 months; P = .002). Although 75% of the intervention group was alive at 1 year, 69% with usual care survived the year (P = .05), with differences also seen in quality-adjusted survival (mean of 8.7 v. 8.0 months; P = .004). Benefits were greater for participants lacking prior computer experience. Most patients receiving intervention (63%) reported severe symptoms during the study. Nurses frequently initiated clinical actions in response to e-mail alerts.
Clinical benefits were associated with symptom self-reporting during cancer care.
利用患者报告的结果来加强常规癌症护理期间的症状监测,这一做法正受到越来越多的关注,但对临床结果影响的证据有限。
我们将纪念斯隆凯特琳癌症中心接受晚期实体瘤常规门诊化疗的患者随机分组,一组通过平板电脑报告12种常见症状,另一组接受由临床医生酌情进行症状监测的常规护理。那些拥有家用电脑的患者在就诊期间会收到每周的电子邮件提示以进行报告。主治医生在就诊时会收到症状打印件,当参与者报告严重或症状恶化时,护士会收到电子邮件警报。主要结局是与基线相比,6个月时健康相关生活质量(HRQL)的变化,通过欧洲五维度健康量表(EuroQol EQ-5D Index)进行测量。次要终点包括急诊室就诊、住院和生存情况。
在766名分配的患者中,干预组中健康相关生活质量改善的参与者比常规护理组更多(34%对18%),恶化的参与者更少(38%对53%;P<.001)。总体而言,干预组的健康相关生活质量平均下降幅度小于常规护理组(下降1.4分对7.1分;P<.001)。接受干预的患者急诊室就诊(34%对41%;P=.02)或住院(45%对49%;P=.08)的频率较低,化疗持续时间更长(平均8.2个月对6.3个月;P=.002)。尽管干预组75%的患者在一年时存活,但常规护理组69%的患者存活了一年(P=.05),在质量调整生存方面也存在差异(平均8.7个月对8.0个月;P=.004)。对于缺乏先前计算机经验的参与者,益处更大。大多数接受干预的患者(63%)在研究期间报告了严重症状。护士经常根据电子邮件警报启动临床行动。
癌症护理期间的症状自我报告与临床益处相关。